Heart Failure With Normal Ejection Fraction
38
4
5
21
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.9%
3 terminated out of 38 trials
87.5%
+1.0% vs benchmark
11%
4 trials in Phase 3/4
38%
8 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (38)
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF
Exercise Intolerance in Heart Failure
Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction
Imaging Histone Deacetylase in the Heart
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
Circulating RNAs in Acute Congestive Heart Failure
Chronic Exogenous Ketosis in HFpEF
Hemodynamic-GUIDEd Management of Heart Failure
Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)
Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure With Preserved Ejection Fraction
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Obesity and HFpEF
LYmphangiogenesis FacTors in Heart Failure States
Cell Therapy in HFpEF
Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF
High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction
Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction
Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension
Cardiopulmonary Interactions in Patients With Heart Failure